CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today results of a study designed to develop and validate its ZemivaTM Normals reference database using gender-based and cardiac ischemia risk stratification parameters. Results indicated that the database accurately differentiated normal from abnormal metabolic heart activity in patients dosed with Zemiva. The Zemiva Normals reference database is designed to enable interpreting physicians to rapidly and quantitatively assess a patient’s cardiac image against normal images contained in the database. Zemiva (iodofiltic acid I 123 or BMIPP) is a molecular imaging pharmaceutical in development by Molecular Insight for the diagnosis of cardiac ischemia, due to insufficient blood supply to the heart muscle, in patients with suspected acute coronary syndrome (ACS) in the emergency department setting. The data were presented in a poster presentation on September 6, 2007 at the annual meeting of the American Society of Nuclear Cardiology (ASNC) in San Diego, CA.
